PMD26 COST-ASSESSMENT RE-CONSIDERED: THE CASE OF HIP FRACTURE  by Brock, EM
801Abstracts
HTA will not be the appropriate instrument for its own,
but should be used in combination with comprehensive
HTA.
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The time inconsistency of decisions (TID) is the phenom-
enon, studied in various domains of economics, when a
decision is optimal from the perspective of one moment
in time and ceases being so in a subsequent moment.
OBJECTIVES: The aim of the study was to check for the
feasibility of prevailing of the TID in the pharmacoeco-
nomic sequential decision problems as well as to identify
the impact of this phenomenon on the process of decision
implementation and its outcomes. METHODS: A formal
model of sequential decision problems, both with and
without uncertainty, based on a graph theory, was pro-
vided. In such a framework the decision problem is rep-
resented by a graph and a set of functions over the vertices
representing the costs, effects and the probability distrib-
utions; decision alternatives are subgraphs; alternatives
are described by the expected values of costs and effects;
the rule of choice is to minimize criterion function of the
expected cost and effectiveness, representing the prefer-
ences of a decision maker. The ﬂow of time can be mod-
elled by analyzing subsequent decision problems, called
reduced problems, being the subgraphs of the original
problem obtained by cutting the original graph in a
certain vertex. RESULTS: There exist criteria susceptible
to TID phenomenon, in particular the cost-effectiveness
criterion is susceptible to TID in problems both with and
without uncertainty and cost-beneﬁt criterion or incre-
mental cost-effectiveness criterion are resistant to TID in
these kinds of problems. TID can lead actual decision
makers to behave differently than advised accordingly to
the model solutions and can make them choose actions
that lead to pareto-nonoptimal decisions. CONCLU-
SIONS: The TID is immanently present in pharmaco-
economic decision problems as the widely used
cost-effectiveness criterion is susceptible to it. It causes
ambiguities in decision problem solving as the actual deci-
sion maker(s) may not stick to the model solution in a
real life. The effect of this phenomenon can be pareto-
nonoptimal behaviour.
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OBJECTIVE: Hip fracture has long been associated with
signiﬁcantly increased morbidity as well as mortality. It is
argued that the currently available methodological guid-
ance on cost assessment falls short of distinguishing
between costs associated with a hip fracture and costs
associated with “old age”. METHODS: It is suggested
that additional insight into this question can be gained by
linking data on a patient’s resource consumption with his
or her outcomes data: In order to establish that costs were
directly attributable to the sustained hip fracture, they
needed to be accompanied by corresponding changes in
physical functioning, and changes in physical functioning
which the patient might associate with the sustained hip
fracture rather than “old age”. An analysis of the incre-
mental health and social care costs associated with 449
hip fractures in Tayside, Scotland (UK) in the year fol-
lowing the fracture suggests that in only a minority of
patients did long-term costs due to changes in accommo-
dation needs coincide with a decline in physical func-
tioning. RESULTS: Even fewer patients attributed any
changes that did occur in this respect to the sustained
fracture. Taking outcomes data into account thus reduced
the costs, which can be directly attributed to a hip frac-
ture by 40% in this patient group. CONCLUSIONS: The
data of this patient group thus appears to suggest that
cost estimates of hip fracture based on current method-
ologies of cost assessment are overestimating the real
costs of the condition by 40%.
METHODOLOGICAL ISSUES—Modeling
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OBJECTIVES: The few decision analytic models of glau-
coma treatment that exist have focused on absolute
reduction (in mmHg) of intraocular pressure (IOP) rather
than achievement of target IOP, which varies greatly 
by patient. We provide an overview of an innovative 
glaucoma model and highlight important modeling 
challenges. METHODS: A simulation model of the man-
agement of patients with open-angle glaucoma and/or
ocular hypertension was developed in Microsoft Excel.
The model examined competing strategies involving
sequential use of up to six interventions with switches
based on the monthly probability that a patient was “suc-
cessfully maintained” on therapy. These probabilities
were based on discontinuation data from actual clinical
practice. Therapy discontinuation could be due to lack of
IOP control, adverse events, or lack of compliance/
persistence. Outputs of the model include months of
treatment, switching frequency, days of IOP control, 
